World Heart Day - 29 September 2021

Today on World Heart Day, Windrose would like to recognize all of the innovators, healthcare providers, and family caregivers who are striving to make the world a better place for those with cardiovascular diseases (CVD).

CVD is the leading cause of mortality in the world, and includes diseases such as heart failure, stroke, and atrial fibrillation. Risk factors for CVD include diabetes, cholesterol, physical inactivity, and tobacco use.

Recently, multiple classes of type II diabetes drugs have shown cardiovascular benefits in clinical trials. SGLT-2 inhibitors can lower the risk of death from cardiovascular events, and GLP-1 agonists can reduce the risk of cardiovascular events in adults with type II diabetes and heart disease. Benefits have also been shown in adults who do not have type II diabetes.

While the primary indication for these drugs is type II diabetes, assessing cardiovascular benefits in clinical trials can increase the value of these medications and have changed the landscape of therapies and treatment algorithms for CVD such as heart failure. In addition, patients with type II diabetes can benefit from drugs that not only improve glycemic control but also reduce their risks of serious complications from cardiovascular events.

Windrose are fortunate to have partnered with those working to bring therapies to market for patients with CVD.